Novo Nordisk Submits MAA for Oral Semaglutide
Novo Nordisk has announced the submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for oral semaglutide, a glucagon-like peptide-1 (GLP-1) analogue tablet.
To be used as a treatment of adults with Type 2 diabetes, this once-daily oral formulation utilises Emisphere Technologies’ proprietary Eligen® SNAC Carrier Technology.
Oral semaglutide has now been submitted for regulatory approval in the US, the EU and Canada.
More About This Company
Development Update
Novo Nordisk announced the European Commission (EC) has granted marketing authorisation for Rybelsus®, (oral semaglutide),...
Study: Pharmacokinetics of Oral Cyanocobalamin Formulated with SNAC
Originally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label,...
Emisphere Development Update
Novo Nordisk has announced the Federal Food and Drug Administration (FDA) approved Rybelsus, a semaglutide...